TR200103002T2 - PPAR nkleer resept”rleri i‡in yeni ligandlar - Google Patents

PPAR nkleer resept”rleri i‡in yeni ligandlar

Info

Publication number
TR200103002T2
TR200103002T2 TR2001/03002T TR200103002T TR200103002T2 TR 200103002 T2 TR200103002 T2 TR 200103002T2 TR 2001/03002 T TR2001/03002 T TR 2001/03002T TR 200103002 T TR200103002 T TR 200103002T TR 200103002 T2 TR200103002 T2 TR 200103002T2
Authority
TR
Turkey
Prior art keywords
alkyl
receptors
ligands
kleer
ppar
Prior art date
Application number
TR2001/03002T
Other languages
English (en)
Inventor
Tamura Gakuzo
Ando Kunio
Magae Junji
Original Assignee
Nuclear Receptor Research Limited
Institute Of Research And Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuclear Receptor Research Limited, Institute Of Research And Innovation filed Critical Nuclear Receptor Research Limited
Publication of TR200103002T2 publication Critical patent/TR200103002T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Orkil aldehid bölgesinin 2-pozisyonu ve/veya 4-pozisyonundaki hidroksil grup(lar) na ait hidrojen atom(lar) ; C1-15 alkil, C1-15 alkenil, CH2-COOH, CH2COO(C1-15)alkil, C(=O)(C1-15) alkil, C(=O)(CH2)1-15COOH, nikotinoil ya da izonikotinoil vb. ile yer deGiçtiren (substitusyon) en az bir orkil aldehid bölgesine sahip askofuranon ve askofuranon homologlar ile askoklorin homologlar ndan oluçan gruptan seçilen bileçikler olarak nükleer reseptör PPAR' lere (peroksisom proliferatörle aktifleçtirilen reseptörler) ait ligandlar. Bu ligandlar; diyabetler; hipertansiyon veya serebrovasküler hastal klar; arteryoskleroz; diyabet komplikasyonlar ; kronik enflamasyon; kaçeksi; sindirim sistemi kanserleri vb. tedavisi ve/veya önlenmesinde faydal d r.
TR2001/03002T 1999-03-11 2000-03-13 PPAR nkleer resept”rleri i‡in yeni ligandlar TR200103002T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10699699 1999-03-11

Publications (1)

Publication Number Publication Date
TR200103002T2 true TR200103002T2 (tr) 2002-03-21

Family

ID=14447842

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2002/02077T TR200202077T2 (tr) 1999-03-11 2000-03-13 Prar nükleer reseptörleri için yeni ligandlar
TR2001/03002T TR200103002T2 (tr) 1999-03-11 2000-03-13 PPAR nkleer resept”rleri i‡in yeni ligandlar

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2002/02077T TR200202077T2 (tr) 1999-03-11 2000-03-13 Prar nükleer reseptörleri için yeni ligandlar

Country Status (10)

Country Link
EP (1) EP1176134A4 (tr)
KR (1) KR20020010581A (tr)
CN (1) CN1348436A (tr)
AU (1) AU2943300A (tr)
BR (1) BR0009474A (tr)
CA (1) CA2366281A1 (tr)
MX (1) MXPA01009127A (tr)
NO (1) NO20014394L (tr)
TR (2) TR200202077T2 (tr)
WO (1) WO2000053563A1 (tr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
AU2002321229A1 (en) * 2001-08-06 2003-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for identifying anti-inflammatory drugs
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
EP1481670A4 (en) * 2002-01-31 2005-07-13 Arigen Inc PHARMACEUTICAL COMPOSITION FOR THE DIAGNOSIS, PREVENTION OR TREATMENT OF A MULTIFACTOR SYNDROME
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
ATE513807T1 (de) * 2003-02-24 2011-07-15 Nrl Pharma Inc Neuer transkriptionsfaktor, dessen herstellungsverfahren und verwendung
JP2005126343A (ja) * 2003-10-22 2005-05-19 Inst Of Research & Innovation 免疫抑制用薬剤組成物
JP4545463B2 (ja) * 2004-02-16 2010-09-15 武 北原 新規転写因子の製造法及び用途
EP1772143A4 (en) * 2004-05-20 2009-12-30 Arkray Inc ACTIVATOR OF PPAR (PEROXISOMEPROLIFERATORACTIVATED RECEPTOR) AND MEDICAMENTS, ADDITIVES, FUNCTIONAL FOODS AND FOOD ADDITIVES USING THIS
KR100986817B1 (ko) * 2008-06-03 2010-10-08 주식회사 이에스파워 태양광 장치의 방어방법 및 방어시스템
JP5546807B2 (ja) * 2009-07-01 2014-07-09 サントリーホールディングス株式会社 Ｐｐａｒリガンド剤
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
KR102051693B1 (ko) 2012-05-29 2019-12-03 가부시키가이샤 미토콘도리아 겐큐쇼 디히드로오로토산 탈수소효소 억제제
EP3383384A4 (en) * 2015-12-01 2019-08-07 Theriac Biomedicale Inc. PPAR-GAMMA ACTIVATORS AND THEIR THERAPEUTIC USES
JP6758669B2 (ja) 2016-01-05 2020-09-23 達雄 星野 アスコクロリン誘導体およびａｍｐｋ活性化剤としてのその使用
JP7102006B2 (ja) 2017-05-18 2022-07-19 達雄 星野 アスコクロリン誘導体を用いた併用療法
WO2018216821A1 (en) * 2017-05-23 2018-11-29 Nrl Pharma, Inc. Use of ascochlorin derivative for combination therapy
CN111050759A (zh) 2017-09-15 2020-04-21 雀巢产品有限公司 用于预防和治疗神经障碍的杂萜化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3546073A (en) * 1968-08-13 1970-12-08 American Cyanamid Co Fusarium fermentation
US3995061A (en) * 1974-04-09 1976-11-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition and method of using the same
JPS5136450A (en) * 1974-09-20 1976-03-27 Chugai Pharmaceutical Co Ltd Asukofuranonjudotai no seiho
AU493677B2 (en) * 1975-02-28 1976-09-02 Okada Masashi Pharmaceutical composition for arteriosclerosis
GB1498334A (en) * 1976-03-19 1978-01-18 Okada M Ascofuranone derivative and process for preparing the sam
US4500544A (en) * 1981-09-10 1985-02-19 Chugai Seiyaku Kabushiki Kaisha Ascochlorin derivatives, and pharmaceutical composition containing the same
JPS62181271A (ja) * 1986-02-06 1987-08-08 Sagami Chem Res Center ３（２ｈ）−フラノン誘導体
WO1994004520A1 (en) * 1992-08-11 1994-03-03 Immuno Japan Inc. Ascofuranone, and hypolipidemic agent, hypoglycemic agent and glycation inhibitor each containing ascofuranone derivative as active ingredient
JPH0816057B2 (ja) * 1992-09-10 1996-02-21 田村 學造 グリケイション阻害剤
JPH07206838A (ja) * 1994-01-14 1995-08-08 Immuno Japan:Kk 新規なアスコフラノン誘導体並びにそれらを有効成分とする血中脂質低下剤、血糖低下剤、グリケイション阻害剤及び抗酸化剤
US5420334A (en) * 1994-04-04 1995-05-30 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998043081A1 (en) * 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
AU8559598A (en) * 1997-08-08 1999-03-01 Ono Pharmaceutical Co. Ltd. Gamma-type regulators for peroxisome proliferator-activated receptor
WO2000035867A1 (fr) * 1998-12-14 2000-06-22 Nuclear Receptor Research Limited Nouveaux ligands d'un recepteur nucleaire

Also Published As

Publication number Publication date
AU2943300A (en) 2000-09-28
WO2000053563A1 (fr) 2000-09-14
MXPA01009127A (es) 2003-07-14
CA2366281A1 (en) 2000-09-14
TR200202077T2 (tr) 2002-11-21
NO20014394L (no) 2001-11-12
CN1348436A (zh) 2002-05-08
EP1176134A4 (en) 2004-06-30
NO20014394D0 (no) 2001-09-10
EP1176134A1 (en) 2002-01-30
BR0009474A (pt) 2001-11-27
KR20020010581A (ko) 2002-02-04

Similar Documents

Publication Publication Date Title
TR200103002T2 (tr) PPAR nkleer resept”rleri i‡in yeni ligandlar
Gallagher et al. Trends in basal cell carcinoma, squamous cell carcinoma, and melanoma of the skin from 1973 through 1987
TR199900293T2 (tr) Alzheimer hastaligi tedavisi için bir farmasötik bilesim üretmek üzere selat maddesi clioquil'un kullanimi.
BR1100159A (pt) compostos de azetidinona substituìda com hidróxi úteis como agentes hipocolesterolêmicos
FR2695560B1 (fr) Composition cosmétique filtrante photostable contenant un filtre UV-A et un polymère filtre du type silicone benzotriazole.
ATE384035T1 (de) Ether-verbindungen, zusammensetzungen und ihre verwendung
IT8022478A0 (it) Emulsione per l'igiene personale comprendente un copolimero di silossano ossialchilene.
PT873332E (pt) Compostos discodermolida e composicoes farmaceuticas que os contem para terapeutica do cancro
DE69928226T8 (de) Chemokin rezeptor antagonisten und verwendung
DE19781652T1 (de) Selbsteichendes Ringunterdrückungsfilter für die Computertomographie
FR2679134B1 (fr) Compositions cosmetiques pour la regulation de la pigmentation cutanee comprenant un extrait d'eclipta alba.
KR960017677A (ko) 새로운 선스크린제들, 이를 함유하는 광보호성 화장품 조성물 및 그의 용도
EP0972866A3 (en) Device and method for equalising the supply to a carder of textile fibres which are in the form of a mat
McIntosh et al. TETRACYCLINE‐INDUCED TOOTH CHANGES, PART 4 DISCOLORATION AND HYPOPLASIA INDUCED BY TETRACYCLINE ANALOGUES
PT100111A (pt) Composicao para o tratamento de um mamifero sofrendo de doenca proliferativa dapele, benigna ou maligna, compreendendo um analogo de somatostatina
DE69624827T2 (de) 5'-substitutierte-ribofuranosyl benzimidazolen als antivirale.
ES2185321T3 (es) Combinacion de un agonista inverso de gaba-a alfa 5 y un agosnista de la nicotina.
FR2372920A1 (fr) Bande elastique tricotee perfectionnee
HUP0202701A2 (hu) Szubsztituált benziltiazolidin-2,4-dion-származékok és ezeket tartalmazó gyógyszerkészítmények
DE3787239D1 (de) Komplementabhängiger zytolytischer monoklonaler Antikörper gegen Trichomonas vaginalis und seine therapeutische und diagnostische Verwendung.
KR970069025A (ko) 디벤조일메탄 유도체와 다당류 알킬 에테르를 함유하는 광안정성 스크린 조성물, 및 그것의 용도
AL‐FOUZAN et al. Melasma‐like (pigmented) actinic lichen planus
KR920703498A (ko) 칼콘(chalcone) 유도체 및 자외선 방호작용을 갖는 화장료
Satake et al. Therapeutic effects of loxiglumide on experimental acute pancreatitis using various models
IT1305549B1 (it) Apparato di supporto di labbri raschiatori nelle protezioni traslabiliper guide di macchine e relativo metodo di costruzione